Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has entered an agreement with a pharmaceutical company firm to make use of its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
Subscribe to our email newsletter
Access said it will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration.
RNAi is initiated by introducing small fragments of RNA, typically siRNA or miRNA, into cells at disease sites.
Access Pharmaceuticals VP business development and strategy Phillip Wise said the company is happy to have signed an agreement with another major player in RNAi therapeutics.
"We believe the distinct advantages our CobOral and CobaCyte technologies offers is well-suited for the company’s RNAi products and we look forward to the collaborative work ahead," Wise added.